Jingting Luan

Gemcitabine plus Ramucirumab in Pleural Mesothelioma: A Multicenter Real-World Analysis

Rajiv C. Shah, Martin Reck, Petra Hoffknecht, Daniel Christian Christoph et autres

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Rajiv C. Shah, Eva Lotte Buchmeier, Hans‐Georg Kopp, Daniel Christian Christoph et autres

BACKGROUND: Despite the approval of nivolumab/ipilimumab, the prognosis of patients with pleural mesothelioma (PM) remains poor. Although this combination has shown improved survival in the landmark CheckMate (CM)-743 trial, evidence from real-world settings remains limited. METHODS: In this retrospective, multicenter study, the …

de, it (code pays fourni par la source)

First-Line Nivolumab Plus Ipilimumab in Pleural Mesothelioma: Efficacy and Safety Data from the Real-World MesoNet Study

Rajiv C. Shah, Eva Lotte Buchmeier, Hans‐Georg Kopp, Daniel Christian Christoph et autres

de (code pays fourni par la source)

392 A case series of IMA203 TCR-T-cell therapy targeting PRAME in combination with BRAF-/MEK-inhibition in two melanoma patients with active CNS metastases

Friederike Schmitz, Katharina Epp, Martin M. Schumacher, Annkristin Heine et autres

Background Adoptive cell therapy with T-cell receptor-modified T-cells (TCR-T) is emerging as an attractive therapeutic approach in patients with solid tumors. Recently, we have shown promising results of IMA203, a TCR-T product targeting the cancer testis antigen PRAME in heavily pretreated melanoma …

de (code pays fourni par la source)

Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting.

Rajiv C. Shah, Martin Reck, Christian Grohé, Daniel Christian Christoph et autres

8085 Background: The approval of nivolumab/ipilimumab (IO) has extended the first-line treatment options in unresectable pleural mesothelioma (PM). In the Checkmate 743 trial, first-line IO treatment resulted in similar survival benefit for both non-epithelioid (NE) and epithelioid (E) subtype with median survival …

de, it (code pays fourni par la source)

Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Targeted Therapies

Fabian Acker, Jingting Luan, Puyan Soltani Germy, Marcel Kemper et autres

de (code pays fourni par la source)

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient

Sarolta Bojtine Kovacs, Jingting Luan, Sandra Maria Dold, Andreas Weis et autres

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient

de (code pays fourni par la source)

The mitochondrial transporter SLC25A25 links ciliary TRPP2 signaling and cellular metabolism

Alexis Hofherr, Claudia Seger, Fiona Fitzpatrick, Tilman Busch et autres

Cilia are organelles specialized in movement and signal transduction. The ciliary transient receptor potential ion channel polycystin-2 (TRPP2) controls elementary cilia-mediated physiological functions ranging from male fertility and kidney development to left-right patterning. However, the molecular components translating TRPP2 channel-mediated Ca2+ signals …

de, gb, us (code pays fourni par la source)